Loading…
Blockade of receptor for advanced glycation end products improved essential response of inflammation in diabetic wound healing
Background Inflammation in impaired diabetic wound healing has been described as caught in a persistent inflammatory state. Accumulation of advanced glycation end products (AGEs) is closely relevant to impaired diabetic wound. Recent studies identified that blockade of AGEs-RAGE increased neovascula...
Saved in:
Published in: | International journal of diabetes in developing countries 2020-04, Vol.40 (2), p.283-289 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background
Inflammation in impaired diabetic wound healing has been described as caught in a persistent inflammatory state. Accumulation of advanced glycation end products (AGEs) is closely relevant to impaired diabetic wound. Recent studies identified that blockade of AGEs-RAGE increased neovascularization and granulation tissue formation to improving diabetic wound healing.
Objective
This study aimed to evaluate the correlation among the pathogenic effects of AGEs-RAGE, persistent abnormal inflammatory inflammation stage, and impaired wound healing on diabetes.
Methods
Authors examined the levels of inflammatory factor secretion and inflammatory leukocytes infiltration and the connection with AGEs-RAGE interaction on diabetic mice.
Results
Blockade of AGEs-RAGE improved essential secretion of inflammatory factors and infiltration of inflammatory leukocytes in the early inflammatory stage. Furthermore, it also improved the clean of neutrophils by macrophages.
Conclusions
In summary, these findings suggest that rather than a hyper-inflammatory state, diabetic wounds are lack of an essential inflammatory response in the early phase, thus may induce a paradoxical and persistent inflammation state, and AGEs-RAGE play a vital role in these pathogenic progresses. |
---|---|
ISSN: | 0973-3930 1998-3832 |
DOI: | 10.1007/s13410-019-00778-3 |